Brief: HLS Therapeutics Announces That Icosapent Ethyl (Vascepa®) Is Included In The 2021 Canadian Cardiovascular Society (CCS) Guidelines For The Management Of Dyslipidemia For The Prevention Of Cardiovascular Disease In Adults
29/03/2021 11:45
March 29 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES THAT ICOSAPENT ETHYL (VASCEPA®)
IS
INCLUDED IN THE 2021 CANADIAN CARDIOVASCULAR SOCIETY (CCS)
GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIA FOR THE PREVENTION
OF CARDIOVASCULAR DISEASE IN ADULTS
* HLS THERAPEUTICS INC - STRONG RECOMMENDATION FOR USE OF
ICOSAPENT ETHYL FOR PRIMARY PREVENTION AND SECONDARY PREVENTION
* HLS THERAPEUTICS INC - GUIDELINES DO NOT RECOMMEND USE OF
OVER--COUNTER OMEGA-3
Source text for Eikon: ID:nCNWyqSgMa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease